You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Mallinckrodt
Express Scripts
McKinsey
Johnson and Johnson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,810,696

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,810,696
Title:PGLYRP2 biomarker in idiopathic pneumonia syndrome
Abstract: A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.
Inventor(s): Chance; Mark (Chagrin Falls, OH), Cooke; Kenneth (Solon, OH), Schlatzer; Daniela (Lakewood, OH)
Assignee: Case Western Reserve University (Cleveland, OH)
Application Number:14/571,067
Patent Claims:see list of patent claims

Details for Patent 9,810,696

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX search
Ucb Inc CIMZIA certolizumab pegol INJECTABLE; INJECTION 125160 001 2008-04-22   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX search
Centocor Ortho Biotech Inc SIMPONI golimumab INJECTABLE; INJECTION 125289 001 2009-04-24   Start Trial Case Western Reserve University (Cleveland, OH) 2029-06-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
McKesson
Medtronic
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.